Last reviewed · How we verify
Reduced-Dose Daily Buserelin — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Reduced-Dose Daily Buserelin (Reduced-Dose Daily Buserelin) — Tehran University of Medical Sciences.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Reduced-Dose Daily Buserelin TARGET | Reduced-Dose Daily Buserelin | Tehran University of Medical Sciences | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Reduced-Dose Daily Buserelin CI watch — RSS
- Reduced-Dose Daily Buserelin CI watch — Atom
- Reduced-Dose Daily Buserelin CI watch — JSON
- Reduced-Dose Daily Buserelin alone — RSS
Cite this brief
Drug Landscape (2026). Reduced-Dose Daily Buserelin — Competitive Intelligence Brief. https://druglandscape.com/ci/reduced-dose-daily-buserelin. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab